Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 4 2000
Play
Audio Below:
There’s
a trial that’s been started in Austria which has been looking
at Zoladex plus Arimidex as an adjuvant therapy. The randomization
is to Zoladex plus tamoxifen or Zoladex plus Arimidex. The basis
for that is there was a study presented at ASCO last year whereby
patients were randomized either to CMF or to Zoladex plus tamoxifen.
This was in premenopausal, ER-positive patients. And what it showed
was that the early recurrence-free survival curves were in favor
of the endocrine arm. And so they have taken that as the control
arm for the next study, and they’re now comparing Zoladex plus
tamoxifen to Zoladex plus Arimidex.
Formestane
is feasible and effective in elderly breast cancer patients with
comorbidity and disability. Venturino,
A.; Comandini, D.; Granetto, C.; Audisio, R. A.; Castiglione, F.;
Rosso, R., and Repetto, L. (Reprint available from: Venturino A
PO S Lazzaro, Via P Belli 26 I-12051 Alba CN Italy). Breast Cancer
Research & Treatment. 62(3):217-222, 2000 Aug. In process
Critique
of survival update analysis from two phase III anastrozole clinical
trials. Buzdar, A. U.; Wood; Wolter; Vogel; Bland, and Ravdin. Annals
of Surgical Oncology. 6(8 Suppl S):8S-11S, 1999 Dec. No abstract
Letrozole:
Which dose to be used? Buzdar, A. U. Journal of Clinical Oncology. 18(8):1802-1803,
2000 Apr. No abstract
Combined
endocrine therapy for breast cancer - New life for an old idea? Davidson, N. E. (Reprint available from: Davidson NE Johns Hopkins
Oncol Ctr 1650 Orleans St,Rm 409 Baltimore, MD 21231 USA). Journal
of the National Cancer Institute 92(11):859-860, 2000 Jun 7. No
abstract
